ALLOSOURCE

Allosource specializes in the development and delivery of advanced allograft skin products for critical burn care applications, operating within the blood and organ banking sector. Their core capabilities center on the processing, preservation, and clinical deployment of human-derived tissue grafts, with demonstrated expertise in thermal burn therapy using cryopreserved allograft skin. The company applies stringent aseptic processing, tissue banking protocols, and regulatory-compliant sterilization techniques to produce viable, off-the-shelf biological dressings that promote wound closure and reduce infection risk. Their technical proficiency lies in donor screening, tissue characterization, cryopreservation, and quality assurance systems aligned with AABB and FDA standards for human cells and tissues. Allosource differentiates itself through its focus on scalable, clinically validated allograft solutions tailored for acute trauma and burn units in institutional settings. The company has delivered its tissue-based therapies to the Department of Health and Human Services, indicating a focused relationship with federal health agencies responsible for trauma care, disaster response, and military medical support. This engagement reflects a niche but vital role in supplying biological dressings for federal medical facilities and emergency preparedness programs. Allosource operates primarily within NAICS 621991, which encompasses blood and organ banks and related tissue banking services. Their market positioning is highly specialized, serving the regenerative medicine segment of federal healthcare with biologics that bridge the gap between traditional wound care and advanced tissue reconstruction. As an 8H-certified entity based in Centennial, Colorado, Allosource functions as a small business with a targeted geographic footprint centered on federal medical procurement channels. While no additional certifications are listed, their operational model is grounded in compliance with federal tissue banking regulations and clinical safety standards for human allografts.